VIR-2218
Sponsors
Vir Biotechnology Inc., Vir Biotechnology, Inc., Brii Biosciences Limited, Gilead Sciences, Virion Therapeutics
Conditions
Chronic Hepatitis BChronic Hepatitis B Virus (HBV) InfectionChronic Hepatitis B Virus InfectionChronic Hepatitis D Virus (HDV) InfectionCirrhosisHepatic ImpairmentHepatitis B, ChronicHepatitis D, Chronic
Phase 1
Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
CompletedNCT03672188
Start: 2018-11-14End: 2020-09-03Updated: 2021-12-13
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
RecruitingNCT05484206
Start: 2022-09-21End: 2027-04-30Target: 144Updated: 2025-06-13
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
CompletedNCT05612581
Start: 2023-05-10End: 2025-08-19Updated: 2026-02-09
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
CompletedNCT05844228
Start: 2023-06-01End: 2025-04-21Updated: 2025-06-13
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
Active, not recruitingNCT06070051
Start: 2023-09-26End: 2026-03-31Target: 56Updated: 2025-05-30
Phase 2
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
CompletedNCT04412863
Start: 2020-07-03End: 2024-03-25Updated: 2024-09-19
Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China
CompletedNCT04507269
Start: 2020-08-18End: 2021-09-30Updated: 2024-08-26
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Active, not recruitingNCT04856085
Start: 2021-07-11End: 2026-03-31Updated: 2025-10-21
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
CompletedNCT04891770
Start: 2021-08-14End: 2024-07-19Updated: 2025-07-24
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Active, not recruitingNCT05461170
Start: 2022-09-17End: 2029-08-31Updated: 2025-10-14
A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants with Chronic Hepatitis D Virus Infection (SOLSTICE)
Active, not recruitingCTIS2024-512203-40-00
Start: 2022-11-24Target: 119Updated: 2025-11-20
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection
Active, not recruitingCTIS2024-513177-48-00
Start: 2022-06-16Target: 24Updated: 2025-12-02
A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
CompletedCTIS2024-513176-17-00
Start: 2023-03-30End: 2025-08-19Target: 13Updated: 2025-09-03
A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy versus Bulevirtide in Participants with Chronic HDV Infection (ECLIPSE 3)
Active, not recruitingCTIS2024-520062-54-00
Start: 2025-07-23Target: 42Updated: 2026-01-07
Phase 3
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in
Participants with Chronic HDV Infection (ECLIPSE 1)
Active, not recruitingCTIS2024-515919-22-00
Start: 2025-06-02Target: 27Updated: 2025-11-24
A Phase 3 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide (ECLIPSE 2)
RecruitingCTIS2024-519282-22-00
Start: 2025-07-09Target: 136Updated: 2026-01-14